Cutaneous Methotrexate-Related Epstein–Barr Virus-Positive Diffuse Large B-Cell Lymphoma in a Patient with Granulomatous Cutaneous T-Cell Lymphoma: A Case Report and Literature Review
Issued Date
2023-01-01
Resource Type
eISSN
11787015
Scopus ID
2-s2.0-85168281275
Journal Title
Clinical, Cosmetic and Investigational Dermatology
Volume
16
Start Page
2229
End Page
2235
Rights Holder(s)
SCOPUS
Bibliographic Citation
Clinical, Cosmetic and Investigational Dermatology Vol.16 (2023) , 2229-2235
Suggested Citation
Kositkuljorn C., Rutnin S., Rattananukrom T., Puavilai T., Khiankaew B., Boonsakan P., Iamsumang W. Cutaneous Methotrexate-Related Epstein–Barr Virus-Positive Diffuse Large B-Cell Lymphoma in a Patient with Granulomatous Cutaneous T-Cell Lymphoma: A Case Report and Literature Review. Clinical, Cosmetic and Investigational Dermatology Vol.16 (2023) , 2229-2235. 2235. doi:10.2147/CCID.S419534 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/88869
Title
Cutaneous Methotrexate-Related Epstein–Barr Virus-Positive Diffuse Large B-Cell Lymphoma in a Patient with Granulomatous Cutaneous T-Cell Lymphoma: A Case Report and Literature Review
Author's Affiliation
Other Contributor(s)
Abstract
Methotrexate-related lymphoproliferative disorders (MTX-LPDs) are immunodeficiency diseases following methotrexate (MTX) administration, mainly occurring in rheumatoid arthritis patients. Although uncommon, MTX-LPDs have been reported in some patients with psoriasis, dermatomyositis, and cutaneous T-cell lymphoma (CTCL) who received MTX. Granulomatous mycosis fungoides (GMF) is a rare subtype of cutaneous T-cell lymphoma, where MTX is one of the treatment options in recalcitrant cases. Herein, we report a case of a 72-year-old female patient with GMF who additionally developed cutaneous Epstein–Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) during MTX treatment. According to the 5th edition of the WHO classification of Haematolymphoid Tumors (WHO-HAEM), this condition is currently categorized as “lymphoma arising in immunodeficiency/dysregulation”. In this article, we also reviewed published literature on cutaneous MTX-LPDs in the setting of CTCL. This entity should be considered in cases of new, atypical skin nodules and/or plaques in CTCL patients receiving long-term MTX treatment.